Skip to main content
Premium Trial:

Request an Annual Quote

GeneFormatics, Three Bruker Cos. Pen Deals to Develop Proteomics Technologies

NEW YORK, Oct. 3 – Structural proteomics company GeneFormatics said Wednesday that it would work with three Bruker companies to jointly develop proteomics technologies. 

Under the terms so of the deal, GeneFormatics will work on nuclear magnetic resonance spectroscopy with Bruker BioSpin, on X-ray single crystal diffraction with Bruker AXS, and on Matrix Assisted Laser Desorption/Ionization Time-of-Flight mass spectrometry with Bruker Daltonics.

In exchange, the Bruker companies will contribute to GeneFormatics’ next round of private financing, and GeneFromatics will also make an equity investment in Bruker AXS and Bruker Daltonics.

The companies did not disclose the size of the equity stakes or say how many employees they would dedicate to the projects. A GeneFormatics spokeswoman was not immediately available for comment.

"GeneFormatics' approach breaks through the structural proteomics bottleneck by using 3-D analysis technologies, such as ours, only on those proteins of greatest medical or chemical interest," Frank Laukien, CEO of Bruker Daltonics and chairman of Bruker AXS, said in a statement. "We see high value in what GeneFormatics' scientists and consultants will provide to us in advancing our technologies.”

GeneFormatics of San Diego, which initially specialized in computationally predicting protein structure, has been expanding its proteomics capabilities over the last year. In January, the company acquired Structure Function Genomics, a Princeton, N.J.-based company that has developed high-throughput NMR techniques for determining protein structure. 

And, in April, GeneFormatics announced its intention to delve into x-ray crystallography.

"With these agreements, GeneFormatics will further enhance its already state-of-the-art 3-D structure analysis technologies by collaborating with a group of the leading life science systems manufacturers in the world," John Chiplin, CEO of GeneFormatics, said in the statement.

Under the terms of the deal, GeneFormatics said it would also serve as a test site for new biological mass spectrometry, X-ray SCD, and NMR spectroscopy technologies as they are developed by the Bruker companies.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.